IL6 and neoplasm: Activation of inflammatory responses releases various growth factors (GFs) and pro-inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1 (IL-1), and tumor necrosis factor-α (TNF-α) (20), altering catabolism in tumor patients.